Mental Health UK
UK burnout research: workplace support needs to reach the working day
UK archive · Original report: 16 January 2026. Mental Health UK’s 2026 survey highlights the gap between mental-health awareness and practical support at work.
SHIFT Newsroom
SHIFT Newsroom
UK health, NHS access and medicine updates, followed by international research worth understanding. Clear sources, evidence limits and what each story means here.
23 UK updates · 105 international updates.
Showing 128 stories
No stories match these filters. Try another combination or clear your selection.
UK health and access
Scottish Government
Scotland’s prevention plans: why weight management goes beyond a prescription
UK archive · Original report: 17 June 2025. Two ten-year frameworks published in June 2025 placed prevention, healthier food environments and care closer to home on Scotland’s agenda.
MHRA
Foundayo approved in the UK: what the orforglipron decision means
UK archive · Original report: 10 August 2026. The MHRA’s August 2026 decision covers weight management and type 2 diabetes. It does not by itself create NHS access or confirm private stock.
NHS England
England’s mental-health survey: what the newer figures can tell us
UK archive · Original report: 27 November 2025. The 2023/24 Adult Psychiatric Morbidity Survey, published in stages during 2025, helps describe need. Its figures are not a live count for 2026.
Department of Health Northern Ireland
Northern Ireland’s obesity service: what the first phase actually covers
UK archive · Original report: 29 June 2026. The June 2026 update set out a staged obesity-management service and a separate lifestyle programme. Their entry routes should not be confused.
Scottish Government
Scotland’s mental-health progress report: why delivery needs scrutiny
UK archive · Original report: 11 June 2025. A June 2025 update reviewed Scotland’s mental-health delivery and workforce plans, including progress and the pressures on implementation.
Welsh Government
Wales’ ten-year mental-health strategy: the plan behind the promise
UK archive · Original report: 30 April 2025. Wales published a new mental-health and wellbeing strategy in April 2025, alongside an initial delivery plan running to 2028.
Department of Health and Social Care
England’s first men’s health strategy: what matters beyond the launch
UK archive · Original report: 18 November 2025. The November 2025 strategy brought men’s physical and mental health together. Its commitments still need to be judged by delivery.
Department of Health and Social Care
England’s mental-health expansion: what is planned to open, and when
UK archive · Original report: 5 August 2026. A £343 million announcement covers 100 community centres and 59 mental-health emergency departments. Many are planned facilities, rather than services open today.
NHS England
A 24-hour mental-health centre in Tower Hamlets: what changed
UK archive · Original report: 17 July 2025. The first of six neighbourhood mental-health pilots opened in July 2025, bringing clinical and practical support into one local service.
NHS England
Men and NHS talking therapies: what London’s feedback really shows
UK archive · Original report: 9 June 2025. Positive feedback from men who completed talking therapies is encouraging. It is a satisfaction finding, not a 92% cure rate.
NHS England
NHS Mounjaro access in England: why the route still matters
UK archive · Original report: 2 April 2026. April 2026 commissioning guidance explains phased access to tirzepatide, and why national eligibility is not the same as an immediate prescription.
NICE
After weight-loss treatment: why follow-up belongs in the plan
UK archive · Original report: 5 August 2025. NICE’s August 2025 quality standard put support after treatment in focus. NHS England’s 2026 guidance keeps that issue relevant.
UCL
Weight-loss medicine use in Britain: what the survey says about men
UK archive · Original report: 8 January 2026. A Great Britain survey published in January 2026 offers a snapshot of medicine use, including a marked difference between men and women.
UCL
Less-processed food and weight loss: what a UK trial found
UK archive · Original report: 4 August 2025. A small UK feeding trial compared two diets that both followed healthy-eating guidance. The result deserves attention, with limits.
NHS England
Pharmacy First expansion: what changes in England this autumn
What the planned expansion means for local pharmacy care, including who can provide it and what to check before travelling.
MHRA
MHRA Warns of Potential Risk of Pulmonary Aspiration with GLP-1 and Dual GIP/GLP-1 Receptor Agonists
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the potential risk of pulmonary aspiration during general anaesthesia or deep sedation with GLP-1 and dual GIP/GLP-1 receptor agonists
MHRA
MHRA Issues Reminder on GLP-1 Receptor Agonists' Potential Side Effects and Misuse
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals of the potential side effects and misuse of GLP-1 receptor agonists.
MHRA
Semaglutide (Wegovy, Ozempic and Rybelsus): Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus)
MHRA
Rybelsus (semaglutide tablets) formulation change poses medication error risk
The MHRA has issued a drug safety update regarding the transition to a new formulation of Rybelsus (semaglutide tablets), highlighting the risk of medication errors.
MHRA
Warning over falsified Mounjaro KwikPen 15mg pre-filled pens in the UK
The MHRA has issued a warning about falsified Mounjaro KwikPen 15mg pre-filled pens, which may pose a risk to users
MHRA
Strengthened Warnings for GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists
The MHRA has issued strengthened warnings on acute pancreatitis, including necrotising and fatal cases, for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.
MHRA
Wegovy tablet approved in the UK: what the new needle-free route means
The MHRA has approved a once-daily Wegovy tablet for weight management in eligible adults in the UK.
International research and developments
Europe PMC
Childhood obesity care: narrative review preprint
A narrative review preprint examines family support, behavioural care and medicine-related research in childhood obesity. This version has not been peer reviewed.
Europe PMC
Research Update on Glucagon-like Peptide-1 Receptor Agonists
A recent study published on Europe PMC explores the relationship between vagal activity related events and glucagon-like peptide-1 receptor agonists.
Europe PMC
GLP-1 prescribing patterns: research preprint
A preprint examines obesity and GLP-1 prescribing in a large integrated health system. It has not been peer reviewed.
Europe PMC
Research Explores Link Between Diet and GLP-1 Biology in Metabolic Dysfunction and Aging
A new study published on Europe PMC examines the interactions between dietary intake and GLP-1 biology, shedding light on implications for metabolic dysfunction and aging.
Europe PMC
Glucagon-like Peptide-1 Receptor Agonists May Reduce Infection Risk After Knee Replacement
Research suggests that using Glucagon-like Peptide-1 receptor agonists could decrease the risk of periprosthetic joint infection following total knee arthroplasty.
Europe PMC
GLP-1 Receptor Agonists and Rotator Cuff Repair Outcomes
Research explores the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repair.
Europe PMC
GLP-1 Receptor Agonists in Dermatology: Ethical Considerations
Researchers are exploring the use of GLP-1 receptor agonists in dermatology, but ethical considerations must be taken into account.
Europe PMC
Research Highlights Lean Mass Reduction During Weight Loss Induced by Glucagon-like Peptide-1 Receptor Agonists
A recent study published on Europe PMC explores the clinical significance of lean mass reduction during weight loss induced by Glucagon-like Peptide-1 Receptor Agonists, prompting a reevaluation of its implications.
Europe PMC
Research Highlights Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy
A recent viewpoint published on Europe PMC discusses the role of digital behavioral infrastructure in enhancing persistence, tolerability, and postcessation durability of Glucagon-Like Peptide-1 pharmacotherapy.
Europe PMC
Researchers to Study Impact of GLP-1 Receptor Agonists on Intraductal Papillary Mucinous Neoplasms
A new multicentric cohort study aims to investigate the effects of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms
Europe PMC
GLP-1 Receptor Agonists May Have Different Effects on Cardiovascular, Renal, and Liver Outcomes in Type 2 Diabetes Patients
Research published on Europe PMC explores the association between GLP-1 receptor agonists and other antidiabetic medications on various health outcomes in patients with type 2 diabetes.
PubMed / NLM
Obesity Medicine Association Issues Clinical Practice Statement on Obesity and Cardiovascular Disease
A new clinical practice statement from the Obesity Medicine Association highlights the link between obesity and cardiovascular disease
Europe PMC
Research Update on GLP-1 Analogs
A new study provides a structural overview of GLP-1 analogs, which could have implications for the treatment of certain conditions.
Europe PMC
UBT251 Injection Enters Phase 1a/1b Trials for Safety and Efficacy
A randomized, placebo-controlled study assesses the safety, pharmacokinetics, and pharmacodynamics of UBT251, a GLP-1/GIP/GCG receptor agonist injection.
Europe PMC
Semaglutide's Link to Suicidality in Adults with Overweight or Obesity Investigated
A Bayesian meta-analysis of randomized trials examines the relationship between semaglutide and suicidality in adults with overweight or obesity
Europe PMC
Expert Panel Review of Resmetirom and Semaglutide for MASH-Related Fibrosis
An international expert panel has reviewed the use of resmetirom and semaglutide in managing MASH-related fibrosis, providing a clinical practice update.
ClinicalTrials.gov
Dual GIP/GLP-1 Receptor Agonist Being Investigated for Obese Women Before Frozen Embryo Transfer
A clinical trial is underway to study the effects of a Dual GIP/GLP-1 Receptor Agonist in obese women before frozen embryo transfer.
ClinicalTrials.gov
Cagrilintide Under Investigation for Bone Metabolism Role
Researchers are exploring the potential of Cagrilintide, an amylin analogue, in bone metabolism, with a clinical trial currently underway.
ClinicalTrials.gov
Tirzepatide and Levonorgestrel IUD Therapy Being Investigated for EIN and Early-Stage Endometrial Cancer
A clinical trial is underway to explore the efficacy of Tirzepatide and Levonorgestrel IUD Therapy for Endometrial Intraepithelial Neoplasia (EIN) and early-stage endometrial cancer.
ClinicalTrials.gov
The Evira Study Explores Additional Support for Obesity Treatment
A new study, known as The Evira Study, is investigating the impact of additional support during obesity treatment, as listed on ClinicalTrials.gov.
ClinicalTrials.gov
Semaglutide Investigated for Alcohol Use Disorder After Metabolic and Bariatric Surgery
A clinical trial is exploring the use of Semaglutide for Alcohol Use Disorder in patients who have undergone Metabolic and Bariatric Surgery
ClinicalTrials.gov
Tirzepatide Investigated for Obesity-Driven Endometrial Cancer
A clinical trial is underway to explore the potential of Tirzepatide in treating endometrial cancer linked to obesity.
ClinicalTrials.gov
Trial Evaluates Switching from Semaglutide to Zovaglutide in Adults with Obesity
A study is assessing the safety and tolerability of switching from Semaglutide to Zovaglutide in adults with obesity, as listed on ClinicalTrials.gov.
Europe PMC
New Research on Pharmacological Management of Obesity
A recent study published on Europe PMC discusses the current landscape and emerging therapies for the pharmacological management of obesity.
Europe PMC
GLP-1 Receptor Agonists Linked to Gastroesophageal Reflux Disease in Global Pharmacovigilance Analysis
A cross-national signal validation study has investigated the association between GLP-1 receptor agonists and gastroesophageal reflux disease, highlighting the need for further review.
Europe PMC
GLP-1 Receptor Agonists and Eye Condition: A Case Study
Researchers explore potential link between GLP-1 receptor agonist exposure and non-arteritic anterior ischaemic optic neuropathy in an illustrative case.
Europe PMC
Research Update on GLP-1-Based Therapy Use Before and After Pregnancy
A recent study published on Europe PMC explores trends in the use of GLP-1-based therapy before and after pregnancy, highlighting the need for further evidence.
Europe PMC
GLP-1 Receptor Agonists Show Promise for Dermatologic Comorbidities
Research is ongoing into the potential therapeutic benefits of GLP-1 Receptor Agonists for skin-related conditions
Europe PMC
Global Meta-Analysis Explores GLP-1 Nutritional Paradox
A new study examines the relationship between GLP-1, sarcopenic risks, and micronutrient gaps in the post-obesity era
PubMed / NLM
Research suggests Glucagon-like Peptide-1 Receptor Agonists may help with osteoarthritis and inflammatory arthritis
A study published on PubMed indicates that Glucagon-like Peptide-1 Receptor Agonists could reduce disease activity and progression in osteoarthritis and inflammatory arthritis
Europe PMC
Glucagon-like Peptide-1 Receptor Agonist Linked to Injection Site and Dermatologic Reactions
Research highlights potential side effects of Glucagon-like Peptide-1 Receptor Agonist injections, including skin reactions at the injection site.
Europe PMC
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review
Researchers are investigating the potential of Glucagon-Like Peptide-1 Receptor Agonists in treating Obstructive Sleep Apnea, but more evidence is needed.
PubMed / NLM
Research into preoperative weight loss using Glucagon-Like Peptide-1 Agonists before total joint arthroplasty
A study has been published on the use of novel Glucagon-Like Peptide-1 Agonists for preoperative weight loss in total joint arthroplasty patients
Europe PMC
New Research on Obesity Medications Emerges
A recent study published on Europe PMC discusses the evolution of medications for obesity management, but details on specific medicines and their UK status are unclear.
Europe PMC
Research Update on Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists
Recent advances in the treatment of obesity and type 2 diabetes have been reported in a new research update.
PubMed / NLM
Research Explores GLP-1 Receptor Agonists for Adolescent Obesity
A recent study published on PubMed discusses the potential of GLP-1 receptor agonists in treating adolescent obesity, focusing on incretin-based therapies during a sensitive developmental period.
PubMed / NLM
Research Explores Opposite Approaches to Obesity Treatment
A study published on PubMed examines the efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
PubMed / NLM
New Research on Obesity-Driven Heart Failure
A systematic review explores the link between obesity and heart failure with preserved ejection fraction (HFpEF), providing a therapeutic framework for treatment.
PubMed / NLM
Systematic Review Investigates Malnutrition and Metabolic Failure in High-Potency Incretin Therapy
A recent systematic review and meta-analysis explores the relationship between high-potency incretin therapy and the risk of malnutrition and metabolic failure.
Europe PMC
New Review of Pharmacotherapies for Adolescent Obesity
A recent evidence-based review explores current and forthcoming pharmacotherapies for adolescent obesity, highlighting the need for further research and consideration of treatment options.
Europe PMC
Research Highlights Potential of GLP-1 Agonists in Managing MASH-Related Fibrosis
A recent study published on Europe PMC explores the emerging role of GLP-1 mono, dual, and triple agonists in treating MASH-related fibrosis, indicating potential avenues for management.
Europe PMC
GLP-1 Receptor Agonists Post-Bariatric Surgery Trial Underway
Researchers are investigating the use of GLP-1 receptor agonists after bariatric surgery, with a new trial publishing its rationale, design, and baseline characteristics.
PubMed / NLM
Research on Glucagon-Like Peptide-1 Receptor Agonists and Their Effects on Chemosensory Function and Ingestive Behavior
A study published on PubMed explores the impact of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior, but more evidence is needed to fully understand their effects.
Europe PMC
Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss: An Updated Review
Researchers have published an updated systematic review on the efficacy and safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for weight loss in adults without diabetes.
Europe PMC
Study Highlights Postmarketing Safety Signals of GLP-1-Based Therapies
A multi-source pharmacovigilance study examines medication-use risks of GLP-1-Based Therapies in diabetes and obesity
Europe PMC
Tirzepatide Non-Response and Subsequent Semaglutide Response in Class 2 Obesity
Research indicates some individuals with class 2 obesity may not respond to tirzepatide but could respond to semaglutide.
Europe PMC
Research Update: Weight Loss and Bone Health in People With Obesity and Type 1 Diabetes
A new study explores the effects of Liraglutide, Semaglutide, or Tirzepatide on body composition and bone health in individuals with obesity and type 1 diabetes.
Europe PMC
Research suggests Tirzepatide may aid weight loss through a unique mechanism
A study indicates Tirzepatide promotes body weight loss independently of appetite suppression, engaging a brain-brown adipose tissue axis
Europe PMC
Study Examines Weight Regain After Stopping Semaglutide or Tirzepatide
A new analysis looks at how weight regain occurs after discontinuing semaglutide or tirzepatide, but more evidence is needed to understand the full implications.
Europe PMC
Semaglutide Shows Promise in Treating Prurigo Nodularis
A recent case report published on Europe PMC highlights the dramatic improvement of treatment-refractory prurigo nodularis following the initiation of semaglutide.
Europe PMC
Tirzepatide and SGLT2 Inhibitors Show Promise for Heart Failure and Obesity
Research suggests a new therapeutic era for heart failure with preserved ejection fraction and obesity, but more evidence is needed
Europe PMC
Case Report: Unilateral Graves' Disease Linked to Tirzepatide in Diabetes Patient
A recent case report published on Europe PMC highlights a rare instance of unilateral Graves' disease developing in a patient with diabetes who was being treated with Tirzepatide.
Europe PMC
Semaglutide May Aid Weight Loss and Reduce Inflammation in Adults with Overweight or Obesity
A systematic review and meta-analysis explores the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults without diabetes
Europe PMC
Study Examines Glycaemic Changes After Semaglutide Discontinuation in Type 1 Diabetes
Researchers analysed the effects of stopping semaglutide in adults with type 1 diabetes using automated insulin delivery
Europe PMC
Research suggests higher dose of semaglutide may lower incidence of neuropsychiatric events
A study found that a higher dose of semaglutide is associated with a lower incidence of neuropsychiatric events, independent of weight loss
Europe PMC
Researchers Explore Dual-Transporter-Targeted Oral Semaglutide Nanomicelles for Obesity and Diabetes
A new study published on Europe PMC investigates the potential of oral semaglutide nanomicelles in enhancing intestinal absorption and metabolic reprogramming for obesity and diabetes.
Europe PMC
Research Highlights Semaglutide Bioavailability Limitations and Future Opportunities
A recent study published on Europe PMC discusses the limitations and potential innovations in semaglutide bioavailability, which may impact future treatment options.
Europe PMC
Semaglutide Shows Promise in Slowing Ageing in Female Mice
Research published in a recent study suggests that late-life semaglutide treatment may slow ageing and extend lifespan in female mice.
PubMed / NLM
Review of Analytical Methods for Semaglutide
A comprehensive review of methods for determining semaglutide in pharmaceutical formulations and biological matrices has been published.
Europe PMC
Oral Semaglutide Studied for Effects on Diet and Body Composition in Type 2 Diabetes
A prospective observational study in Japan explores the impact of oral semaglutide on dietary intake and body composition in individuals with type 2 diabetes.
Europe PMC
Semaglutide's Effects on Reproductive Systems Studied in Rats
Researchers investigate the direct effects of Semaglutide on male and female rat reproductive systems, beyond weight loss
PubMed / NLM
Tirzepatide Linked to Improvement in Confluent and Reticulated Papillomatosis in Case Report
A case report suggests that weight loss associated with tirzepatide may improve confluent and reticulated papillomatosis, but more evidence is needed.
Europe PMC
Tirzepatide Shows Promise in Treating Refractory Diabetes in Adult with Prader-Willi Syndrome
A recent case report published on Europe PMC highlights the potential of Tirzepatide in managing refractory diabetes mellitus in an adult female with Prader-Willi syndrome.
Europe PMC
Research Update on Tirzepatide in Obese Mice
A recent study published on Europe PMC explores the effects of Tirzepatide on hematopoietic stem and progenitor cycling and inflammatory monocytes in obese mice.
Europe PMC
Orforglipron Research Explores Weight Loss Maintenance
Study investigates whether oral orforglipron can maintain weight loss after stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment
Europe PMC
Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms
Research update on semaglutide and its potential link to papillary thyroid carcinoma, highlighting the need for further evidence
Europe PMC
Tirzepatide's Link to Atrial Fibrillation in Adults with Overweight or Obesity Under Investigation
Researchers have conducted an updated meta-analysis of randomized controlled trials to explore the relationship between tirzepatide and the incidence of atrial fibrillation in adults with overweight or obesity.
PubMed / NLM
Sleeve Gastrectomy and Tirzepatide Compared for Survival in Stage 5 CKD
Research analysis compares sleeve gastrectomy and tirzepatide for improving survival in patients with stage 5 chronic kidney disease (CKD)
ClinicalTrials.gov
Trial Investigates Balanced Nutritional Tablets for Preventing Micronutrient Deficiencies in Weight Loss Patients
A randomized trial is examining the efficacy of comprehensive multivitamin and mineral supplements in patients using GLP-1 RAs for weight loss.
ClinicalTrials.gov
NNC0174-1213 Trial Update for Overweight or Obesity
A study on NNC0174-1213 is underway to investigate its effects in people with overweight or obesity.
ClinicalTrials.gov
Research Study Compares Blood Levels of Two Cagrilintide Versions in Adults with Excess Weight
A new research study aims to compare the blood levels of two different versions of Cagrilintide in adults with excess body weight.
ClinicalTrials.gov
Trial Investigates Early Reinitiation of Semaglutide After Sleeve Gastrectomy in Young People
A new trial is exploring the effects of restarting semaglutide early after sleeve gastrectomy surgery in youth, according to a listing on ClinicalTrials.gov.
ClinicalTrials.gov
Trial Compares BI 456906 and Semaglutide in Obesity
A study is investigating the effects of BI 456906 and semaglutide on glucagon receptor activity in the liver in people with obesity.
ClinicalTrials.gov
Trevogrumab and Garetosmab with Semaglutide in Clinical Trial for Obesity
A clinical trial is investigating the safety and efficacy of Trevogrumab and Garetosmab with Semaglutide for weight loss, fat loss, and lean mass preservation in adult patients with obesity.
ClinicalTrials.gov
Research Study Investigates CagriSema and Semaglutide for Weight Loss in Obesity
A new study is looking at how two different doses of CagriSema and one dose of Semaglutide can help people with obesity, with or without type 2 diabetes, lose weight.
ClinicalTrials.gov
Orforglipron Being Investigated for Obesity-Related Complications
A clinical trial is underway to study the effects of Orforglipron in participants with overweight at risk of developing obesity-related complications.
ClinicalTrials.gov
Semaglutide's Potential in Restoring Ovulation for Polycystic Ovary Syndrome
A clinical trial is investigating the role of Semaglutide in restoring ovulation in youth and adults with Polycystic Ovary Syndrome.
ClinicalTrials.gov
CagriSema Trial Seeks to Aid Weight Loss in People with Excess Body Weight
A research study is investigating the effectiveness of CagriSema in helping individuals with excess body weight lose weight.
ClinicalTrials.gov
Clinical Trial Update: Cagrilintide and Semaglutide for Overweight or Obesity
A research study is comparing blood levels of Cagrilintide and Semaglutide after single doses of different versions of injectable CagriSema in adults with overweight or obesity.
ClinicalTrials.gov
Trial Investigates HMB and Vitamin D for Preserving Muscle in Older Adults on Semaglutide
A clinical trial is examining the potential of HMB plus Vitamin D to preserve muscle mass in older adults who are starting Semaglutide treatment.
ClinicalTrials.gov
IBI3042 Study Update: Investigating Efficacy in Healthy and Overweight/Obese Participants
A clinical trial update for IBI3042 has been posted on ClinicalTrials.gov, detailing its study in healthy participants and those who are overweight or obese.
ClinicalTrials.gov
Research into GLP-1R's effects on muscle and skeleton underway
A clinical trial is investigating the actions of GLP-1R on muscle and the skeleton, according to ClinicalTrials.gov
ClinicalTrials.gov
Tirzepatide Being Investigated for Endometrial Hyperplasia and Grade 1 Endometrial Cancer
A clinical trial is underway to study the use of tirzepatide, in combination with a progestin intrauterine device, for the treatment of endometrial hyperplasia and grade 1 endometrial cancer.
ClinicalTrials.gov
Incretin Therapies in Obesity-related HFpEF: Clinical Trial Update
A clinical trial on incretin therapies for obesity-related heart failure with preserved ejection fraction (HFpEF) has been registered on ClinicalTrials.gov.
ClinicalTrials.gov
GLP1 Receptor Agonists Being Investigated for Reducing Side Effects in Lung Cancer Patients
Researchers are exploring the potential of GLP1 receptor agonists to mitigate treatment-related side effects in lung cancer patients receiving lorlatinib.
ClinicalTrials.gov
Platform Trial for Pediatric Obesity or Overweight (LY900040) Registered
A platform trial, LY900040, has been registered to investigate treatments for pediatric participants with obesity or overweight.
ClinicalTrials.gov
Bariatric Surgery Compared to Semaglutide and Tirzepatide in Clinical Trial
A clinical trial has been registered to compare the effectiveness of bariatric surgery with Semaglutide and Tirzepatide for weight management.
ClinicalTrials.gov
Semaglutide Being Researched for Non-alcoholic Steatohepatitis (NASH)
A research study is investigating the effectiveness of Semaglutide in people with NASH, a condition characterized by inflammation of the liver.
ClinicalTrials.gov
Trial Launched for Injectable Cagrilintide in People With Excess Body Weight
A new clinical trial is comparing two versions of injectable Cagrilintide with a placebo in individuals with excess body weight.
ClinicalTrials.gov
Global Obesity Study Seeks Multiple Interventions
A master protocol study, LY900038, is investigating various interventions for adult participants with obesity or overweight
ClinicalTrials.gov
Semaglutide Being Investigated for Diabetic Eye Disease in Type 2 Diabetes
A research study is comparing semaglutide to placebo in affecting diabetic eye disease in people with type 2 diabetes
ClinicalTrials.gov
Oral Semaglutide Being Researched for Weight Loss in Adults with Excess Body Weight
A research study is investigating the effectiveness of oral semaglutide for weight loss in adults with excess body weight.
ClinicalTrials.gov
CagriSema Being Compared to Tirzepatide in Type 2 Diabetes Trial
A research study is underway to compare the efficacy of CagriSema and Tirzepatide in lowering blood sugar and body weight in people with type 2 diabetes.
ClinicalTrials.gov
Trial Update: Ribupatide for Obesity Without Diabetes
A clinical trial is comparing the efficacy and safety of Ribupatide with Semaglutide and placebo in participants with obesity who do not have diabetes.
ClinicalTrials.gov
Trial to Assess Efficacy and Safety of AT673 with Semaglutide in Type 2 Diabetes and Overweight/Obesity
A clinical trial is underway to evaluate the efficacy, safety, and tolerability of AT673 co-administered with semaglutide in adults with type 2 diabetes and overweight or obesity.
ClinicalTrials.gov
Enobosarm Enters Proof-of-Concept Study for Weight Loss
A proof-of-concept study has been registered to evaluate the effects of Enobosarm on total body weight, physical function, and safety in patients treated with a GLP-1 receptor agonist for weight loss.
ClinicalTrials.gov
Tirzepatide Being Investigated for Binge-Eating Disorder
A clinical trial is underway to assess the efficacy and safety of Tirzepatide compared to placebo or Lisdexamfetamine Dimesylate for binge-eating disorder.
ClinicalTrials.gov
Trial Begins for RO7204239 and Tirzepatide Combination in Obesity Treatment
A new clinical trial is assessing the efficacy, safety, and tolerability of RO7204239 in combination with Tirzepatide for participants with obesity or overweight and at least one weight-related comorbidity.
PubMed / NLM
Geographical Disparities in Counseling Services for Pediatric Obesity
Research highlights existing geographical disparities in the utilization of counseling services by pediatric patients with obesity, according to a study published on PubMed.
PubMed / NLM
Research Explores Gut-Joint Axis in Metabolic Osteoarthritis
A recent study published on PubMed delves into the complex regulatory mechanisms and potential targeted interventions for the gut-joint axis in metabolic osteoarthritis.
ClinicalTrials.gov
Orforglipron Study for Adolescent Obesity or Overweight with Comorbidities
A clinical trial is investigating Orforglipron (LY3502970) for adolescent participants with obesity or overweight and related comorbidities.
Europe PMC
Research suggests females may be resistant to semaglutide-induced muscle loss
A study on ob/ob mice found that females are completely resistant to semaglutide-induced muscle loss, according to research published on Europe PMC
Europe PMC
Research Review Highlights Importance of Lifestyle Interventions in Treating Acquired Hypothalamic Obesity
A systematic review of randomized controlled trials explores the role of body composition and lifestyle interventions in pharmacological treatment of acquired hypothalamic obesity
Europe PMC
Semaglutide with Metformin Studied for Weight Loss and Fertility in PCOS Patients
A pilot prospective study has been commented on, exploring the effect of Semaglutide with Metformin for weight loss and fertility in Polycystic Ovary Syndrome (PCOS) patients with obesity.
Europe PMC
Virtual GLP-1 Programme with Physical Activity Support for Weight Loss
Researchers evaluate a virtual programme combining GLP-1 and physical activity for healthy weight loss